Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment
Status:
Unknown status
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
Hepatitis during anti-tuberculous treatment (HATT) has been an obstacle in managing TB
patients, especially in those with viral hepatitis. A previous study revealed the risk of
HATT is significantly higher in TB patients with high serum hepatitis B virus (HBV) DNA level
than those with low HBV DNA level. Based on these findings, we thus hypothesize that the risk
of HATT in TB patients with high baseline serum HBV DNA level can be reduced by concomitant
use of anti-HBV agent. In this proposal, we will conduct a prospective randomized clinical
study to assess the reduction of HATT risk by using entecavir in TB patients with high
baseline serum HBV DNA level, and to evaluate the risk of other treatment-related adverse
events in two hospitals.